We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and d... Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. It is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The company's operations are based in South San Francisco, California and it operates in one segment. Show more
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...
First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletionAdditional B-cell mediated autoimmune diseases under...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.09 | -14.1558441558 | 7.7 | 7.96 | 6.47 | 897978 | 7.17111696 | CS |
4 | -4.975 | -42.9434613725 | 11.585 | 11.8388 | 6.47 | 1018607 | 8.55462963 | CS |
12 | -3.93 | -37.2865275142 | 10.54 | 16.24 | 6.47 | 1020864 | 10.31525993 | CS |
26 | 4.61 | 230.5 | 2 | 16.24 | 1.86 | 1528029 | 8.58172254 | CS |
52 | 2.08 | 45.9161147903 | 4.53 | 16.24 | 1.28 | 1477623 | 5.7978523 | CS |
156 | -26.31 | -79.9210206561 | 32.92 | 40.64 | 1.28 | 986614 | 10.65252658 | CS |
260 | -48.14 | -87.9269406393 | 54.75 | 79.16 | 1.28 | 827135 | 12.33825616 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions